Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Insights into real-world use of 177Lu-PSMA-617 in patients with mCRPC

Andrei Gafita • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617
VISION

Andrei Gafita, MD, Johns Hopkins Medicine, Baltimore, MD, discusses the real-world use of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Outcomes are similar to that of the VISION trial (NCT03511664) regarding anti-tumour efficacy, overall survival and toxicity profile. While circulating tumour DNA (ctDNA) biomarkers displayed heterogenous results in patient response outcomes, various PSMA PET biomarkers were positively associated with patient outcome. Artificial intelligence (AI) technology displayed the highest accuracy in identifying non-responders. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrei Gafita

Promising novel clinical biomarkers in patients with mCRPC
1:00
Promising novel clinical biomarkers in patients with mCRPC
Andrei Gafita • 13 Feb 2025
The prognostic value of post-therapy LuPSMA-SPECT/CT in mCRPC
2:39
The prognostic value of post-therapy LuPSMA-SPECT/CT in mCRPC
Andrei Gafita • 13 Feb 2025
RECIP: a novel framework for treatment response evaluation using PSMA-PET/CT in patients with mCRPC
1:11
RECIP: a novel framework for treatment response evaluation using PSMA-PET/CT in patients with mCRPC
Andrei Gafita • 4 Jun 2022
Remaining questions regarding PSMA radioligand therapies
0:44
Remaining questions regarding PSMA radioligand therapies
Andrei Gafita • 4 Jun 2022

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals